Much has been said about the EU Vaccines Strategy in recent weeks and months. Coverage from various media can largely be boiled down to the conclusion that despite good intentions, the EU strategy is simply a case of “too little, too late”. But is there more to this story? How does the roll-out of the EU strategy measure up against the rest of the world? And most importantly, what are our reference points? Join Alex, Harpa, and Vic on a deep dive into the EU Vaccines Strategy and discover the good, the bad, and the ethically questionable elements of the complex world of COVID-19 vaccine distribution.
- Official COVID-19 statistics for the EU/EEA from the European Centre for Disease Prevention and Control (EDCD)
- European Commission data on vaccination rates in the EU
The EU’s Vaccines Strategy
- The EU Vaccines Strategy
- EU and National Institutions involved in the procurement and distribution of vaccines and data collection in the EU/EEA.
- The EU’s regulatory process for evaluation and approval of vaccines and key facts on COVID-19 vaccines.
- “Europe’s Vaccination Problem” (The Daily, 12 April 2021)
- “How Europe fell behind on vaccines” (Politico, 27 January 2021)
- “The European Union’s troubled COVID-19 vaccine rollout” (PIEE, 15 March 2021)
- “How vaccines are made, and why it is hard” (The Economist, 4 February 2021)
- “Inside Pfizer’s Fast, Fraught, and Lucrative Vaccine Distribution” (Bloomberg Businessweek, 4 March 2021)
- “Why manufacturing Covid vaccines at scale is hard” (Chemistry World, 23 March 2021)
- “Industrial Policy Saved Europe’s Vaccine Drive” (Foreign Policy, 10 May 2021)